REGISTRATION RIGHTS AGREEMENT among DURECT CORPORATION as Issuer, and MORGAN STANLEY & CO. INCORPORATED, as Initial Purchaser Dated as of June 18, 2003Registration Rights Agreement • August 8th, 2003 • Durect Corp • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT dated as of June 18, 2003 between DURECT Corporation, a Delaware corporation (the “Company”), and Morgan Stanley & Co. Incorporated, (the “Initial Purchaser”) pursuant to the Purchase Agreement dated June 12, 2003 (the “Purchase Agreement”), between the Company and the Initial Purchaser. In order to induce the Initial Purchaser to enter into the Purchase Agreement, the Company has agreed to provide the registration rights set forth in this Agreement.
INDENTURE By and between DURECT CORPORATION and The Bank of New York, as Trustee Dated as of June 18, 2003Indenture • August 8th, 2003 • Durect Corp • Pharmaceutical preparations • New York
INDENTURE dated as of June 18, 2003 between DURECT Corporation, a Delaware corporation (hereinafter called the “Company”), having its principal office at 10240 Bubb Road, Cupertino, California 95014 and The Bank of New York, a New York banking corporation, as trustee hereunder (hereinafter called the “Trustee”).
DURECT CORPORATION PURCHASE AGREEMENTPurchase Agreement • August 8th, 2003 • Durect Corp • Pharmaceutical preparations • New York
DURECT Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. Incorporated (the “Initial Purchaser”) $50,000,000 principal amount of its 6.25% Convertible Notes due 2008 (the “Firm Securities”) to be issued pursuant to the provisions of an Indenture dated as of June 18, 2003 (the “Indenture”) between the Company and The Bank of New York, as Trustee (the “Trustee”). The Company also proposes to issue and sell to the Initial Purchaser not more than an additional $10,000,000 principal amount of its 6.25% Convertible Notes due 2008 (the “Additional Securities”) if and to the extent that the Initial Purchaser shall have determined to exercise the right to purchase such 6.25% Convertible Notes due 2008 granted to the Initial Purchaser in Section 2 hereof. The Firm Securities and the Additional Securities are hereinafter collectively referred to as the “Securities”. The Securities will be convertible into shares of common stock, par value $0.00
